Pause Video

Our Product Development Pipeline

Our robust product development pipeline is built on a portfolio of proprietary and patented technology. Driven by Lisata’s vision and mission, our pipeline programs are grounded in rational science to identify and treat patients most likely to respond to our targeted therapies. Click on each program to learn more.

CendR Platform® Programs

The CendR Platform® incorporates novel technologies to enable more effective tumor-targeted, tissue penetrating delivery of anti-cancer agents to solid tumors. The Platform can also target non-cancerous, immunosuppressive cells selectively within the tumor to enable a patient’s immune system and/or immunotherapies to fight cancer more effectively.

Indication Pre Clinical Phase 1 Phase 2 Phase 3

Indication: First-Line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)

ASCEND: Gemcitabine/Nab-paclitaxel with certepetide or placebo | Australia/New Zealand
First-Line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
ASCEND: Gemcitabine/Nab-paclitaxel with certepetide or placebo | Australia/New Zealand
Phase 2
Phase 1b/2a: Gemcitabine/Nab-paclitaxel + certepetide | China
Phase 1b/2a: Gemcitabine/Nab-paclitaxel + certepetide | China
Phase 1
iLSTA: Gemcitabine/Nab-paclitaxel/Durvalumab + certepetide | Australia
iLSTA: Gemcitabine/Nab-paclitaxel/Durvalumab + certepetide | Australia
Phase 1
Phase 2b: Gemcitabine/Nab-paclitaxel + certepetide | China
Phase 2b: Gemcitabine/Nab-paclitaxel + certepetide | China
Phase 2

Indication: Pancreatic, Colon, and Appendiceal Cancers

CENDIFOX: FOLFIRINOX + panitumumab with certepetide | United States
Pancreatic, Colon, and Appendiceal Cancers
CENDIFOX: FOLFIRINOX + panitumumab with certepetide | United States
Phase 1

Indication: Cholangiocarcinoma

BOLSTER: Gemcitabine/Cisplatin/Durvalumab with certepetide or placebo | United States
Cholangiocarcinoma
BOLSTER: Gemcitabine/Cisplatin/Durvalumab with certepetide or placebo | United States
Phase 2

Indication: Peritoneal Carcinomatosis (Colon & Ovarian)

Hyperthermic intraperitoneal chemotherapy intraoperative intraperitoneal lavage + certepetide | United States
Peritoneal Carcinomatosis (Colon & Ovarian)
Hyperthermic intraperitoneal chemotherapy intraoperative intraperitoneal lavage + certepetide | United States
Phase 1

Indication: Glioblastoma Multiforme

Temozolomide with certepetide or placebo | Estonia/Latvia
Glioblastoma Multiforme
Temozolomide with certepetide or placebo | Estonia/Latvia
Phase 2

Indication: Locally advanced, non-resectable, Gastroesophageal Adenocarcinoma

iGoLSTA: Nivolumab/FOLFIRINOX + certepetide | Australia
Locally advanced, non-resectable, Gastroesophageal Adenocarcinoma
iGoLSTA: Nivolumab/FOLFIRINOX + certepetide | Australia
Phase 1
Certepetide received Fast Track and Orphan Drug Designations by the U.S. FDA in Pancreatic Ductal Adenocarcinoma, Glioblastoma Multiforme, and Osteosarcoma. Certepetide also received U.S. FDA Rare Pediatric Disease Designation in Osteosarcoma.